Robert Yarchoan

Active 1981–2025

144
Papers
23,056
Citations
90
h-index
139
i10-index

Citations

Citations per year for Robert Yarchoan1982: 5 citations1983: 8 citations1984: 7 citations1985: 20 citations1986: 42 citations1987: 88 citations1988: 102 citations1989: 122 citations1990: 133 citations1991: 109 citations1992: 172 citations1993: 120 citations1994: 96 citations1995: 92 citations1996: 86 citations1997: 77 citations1998: 125 citations1999: 92 citations2000: 98 citations2001: 135 citations2002: 130 citations2003: 120 citations2004: 100 citations2005: 92 citations2006: 104 citations2007: 82 citations2008: 88 citations2009: 83 citations2010: 83 citations2011: 103 citations2012: 85 citations2013: 112 citations2014: 91 citations2015: 97 citations2016: 82 citations2017: 92 citations2018: 61 citations2019: 346 citations2020: 324 citations2021: 388 citations2022: 297 citations2023: 223 citations2024: 406 citations2025: 174 citations2026: 2 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,260 citing papers, 40% of this breakdownChina: 330 citing papers, 5.8% of this breakdownUnited Kingdom: 321 citing papers, 5.7% of this breakdownItaly: 258 citing papers, 4.6% of this breakdownGermany: 254 citing papers, 4.5% of this breakdownFrance: 238 citing papers, 4.2% of this breakdownJapan: 173 citing papers, 3.1% of this breakdownCanada: 144 citing papers, 2.5% of this breakdownAustralia: 124 citing papers, 2.2% of this breakdownSpain: 122 citing papers, 2.2% of this breakdownNetherlands: 113 citing papers, 2% of this breakdownSwitzerland: 107 citing papers, 1.9% of this breakdown
0%40%Other 21.3%

Fields

  • Medicine56.9%
  • Immunology and Microbiology21.2%
  • Biochemistry, Genetics and Molecular Biology15.3%
  • Computer Science1.8%
  • Pharmacology, Toxicology and Pharmaceutics0.9%
  • Chemistry0.8%
  • Other3.1%

Topics

  • HIV Research and Treatment8.6%
  • Viral-associated cancers and disorders7.9%
  • HIV/AIDS drug development and treatment5.8%
  • Lymphoma Diagnosis and Treatment3.8%
  • HIV/AIDS Research and Interventions3.5%
  • Immune Cell Function and Interaction3.4%
  • Other67%

Coauthors

All papers

Open in search
  1. HIV-Associated Cancers and Related Diseases

    Authors: , - New England Journal of Medicine 2018 cited by 509

  2. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

    Authors: , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2019 cited by 239

  3. Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS)

    Authors: , , , , , , , , , , , , , , - Clinical Infectious Diseases 2015 cited by 227

  4. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 192

  5. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fábio E. Leal, Michael S. Lee, J.P. Saint Martin, Marie-Reine Martin, Sam M. Mbulaiteye, Ronald T. Mitsuyasu, Vivian M. Morris, Charles G. Mullighan, Andrew J. Mungall, Karen Mungall, Innocent Mutyaba, Mostafa Nokta, Constance Namirembe, Ariela Noy, Martin D. Ogwang, Abraham Omoding, Jackson Orem, German Ott, Hilary Petrello, Stefania Pittaluga, James D. Phelan, Juan Carlos Ramos, Lee Ratner, Steven J. Reynolds, P Rubinstein, Gerhard Sissolak, Graham W. Slack, Shaghayegh Soudi, Steven H. Swerdlow, Alexandra Traverse‐Glehen, Wyndham H. Wilson, Jasper Wong, Robert Yarchoan, Jean C. Zenklusen, Marco A. Marra, Louis M. Staudt, David W. Scott, Ryan D. Morin - Blood 2022 cited by 86

  6. Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2022 cited by 102

  7. Discovery of Kaposi’s sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA

    Authors: , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2018 cited by 195

  8. An Interleukin‐6–Related Systemic Inflammatory Syndrome in Patients Co‐Infected with Kaposi Sarcoma–Associated Herpesvirus and HIV but without Multicentric Castleman Disease

    Authors: , , , , , , , , , , , , - Clinical Infectious Diseases 2010 cited by 313

  9. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease

    Authors: , , , , , , , , , , , - Blood 2014 cited by 122

  10. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma

    Authors: , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2021 cited by 67

  11. Differential Gene Up-Regulation by Hypoxia-Inducible Factor-1α and Hypoxia-Inducible Factor-2α in HEK293T Cells

    Authors: , , , , - Cancer Research 2005 cited by 307

  12. Kaposi sarcoma herpesvirus-associated cancers and related diseases

    Authors: , , , - Current Opinion in HIV and AIDS 2016 cited by 178

  13. Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade–specific epigenome and transcriptome landscapes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrew J. Mungall, Marco A. Marra - Nature Genetics 2020 cited by 78

  14. Cancer Burden in the HIV-Infected Population in the United States

    Authors: , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2011 cited by 778

  15. Viral, immunologic, and clinical features of primary effusion lymphoma

    Authors: , , , , , , , , , , , , , , , , , - Blood 2019 cited by 139

  16. Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases

    Authors: , , , , , , , , , , , , , , , , , , - Blood Advances 2021 cited by 75

  17. Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection

    Authors: , , , , , , , , , , - Clinical Cancer Research 2021 cited by 50

  18. Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV–MCD) and the KSHV Inflammatory Cytokine Syndrome

    Authors: , , , - Frontiers in Microbiology 2012 cited by 199

  19. Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 139

  20. Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

    Authors: , , , , , , , , , , , , , , - Blood 2020 cited by 51

  21. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease

    Authors: , , , , , , , , , , , , - Blood 2013 cited by 158

  22. Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

    Authors: , , , , , , , , , , , , , , , - Blood 2017 cited by 179

  23. HIV-associated Kaposi sarcoma and related diseases

    Authors: , , - AIDS 2017 cited by 150

  24. Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David H. McDermott, Christopher B. Buck - mSphere 2018 cited by 88